Consequently, MSLN CAR-T-CD39-VHH, engineered to secrete the anti-CD39 antibody OriA631, displays enhanced anti-tumor efficacy alongside reduced antibody-associated toxicity [267]. This evidence concerns the gene ENTPD1 and neoplasm.